Clinical trial · Interventional
Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
Leveraging Technology (STAND-T) to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostate cancer. STAND-T is a digital platform that provides prostate health information, evidence-based materials and resources. STAND-T may help improve health, address symptoms, and promote equity in men with prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STAND-T platform | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
| Text Messages | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Health services research (STAND-T, text messages)
- description
- Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.
- interventionNames
- Other: STAND-T platform
- Other: Survey Administration
- Other: Text Messages
Primary outcomes (1)
- measure
- Completion rate
- timeFrame
- Up to 3 months
- description
- The point estimation and 95% confidence interval (CI) of the percentage of participants who complete the 3-month study will be obtained overall and by race/ethnicity and geography.
Secondary outcomes (2)
- measure
- Participants reported satisfaction level
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years * Ability to understand study procedures and to comply with them for the entire length of the study * Ability of individual or legal guardian/representative to understand an informed consent document and the willingness to sign it * Adenocarcinoma of the prostate * Current or planned anti-androgen therapy (ADT) (oral or injection) with gonadotropin-releasing hormone (GnRH) antagonist or luteinizing hormone releasing hormone (LHRH) agonist * Life expectancy duration of 6 months or longer from date of study consent * Prior and concurrent radiation is allowed * Treatment with concurrent androgen signaling inhibitors is allowed * \< 75 minutes/week of vigorous aerobic exercise based on Godin survey or \< 2 days per week of vigorous activity Exclusion Criteria: * Contraindication to any study-related procedure or assessment * Planned surgery/chemotherapy/immunotherapy/parp inhibitor treatment during the study period * Prior and concurrent investigational therapies * Unable to read/speak English * Unable to access the Internet * Has seen an exercise counselor in the past 6 months for prostate or cardiovascular health * Has seen a dietary counselor in the past 6 months for prostate or cardiovascular health
References
Publications (1)
- DERIVEDWang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR Cancer. 2023 Jun 1;9:e45432. doi: 10.2196/45432. PMID 37261885